Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Chugai to Sign an Agreement to Enter China Medical City
[PDF 212KB]
and to Establish an Import and Sales & Marketing Subsidiary
“Chugai Pharma (China) Co., Ltd (Tentative Name).” -
Roche’s New Subcutaneous Formulation of RoACTEMRA
[PDF 270KB]
Gains CHMP Positive Opinion in Europe
for Moderate to Severe Rheumatoid Arthritis -
Personnel Changes
[PDF 125KB] -
Anti-Cancer Agent “Avastin®,”
[PDF 289KB]
Obtained Approval for Additional Indication of Ovarian Cancer -
Anti-Cancer Agent, Antibody Drug Conjugate “Kadcyla®”
[PDF 182KB]
Postponement of Price Listing on the NHI Reimbursement List and
Implementation of a New Clinical Study -
Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of
[PDF 53KB]
Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia
Syndrome Related to Non-Small Cell Lung Cancer in Top EU Markets -
Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2013-2014 Season
[PDF 133KB] -
Roche Gains FDA Approval for New Subcutaneous Formulation
[PDF 188KB]
of ACTEMRA for Use in Adult Patients Living with
Moderately to Severely Active Rheumatoid Arthritis -
F. Hoffmann-La Roche Announces Third Quarter Sales 2013
[PDF 31KB] -
Chugai Renews its “Story of Biotechnology” Website
[PDF 279KB] -
New Drug Application Filed for ALK Inhibitor “Alectinib Hydrochloride”
[PDF 182KB]
for the Treatment of ALK Fusion Gene Positive
Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer -
First HER2 targeted Antibody Drug Conjugate “Kadcyla®,”
[PDF 182KB]
an Anti-Cancer Agent,
Approved for HER2-positive Inoperable or Recurrent Breast Cancer -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 222KB] -
Launch of the Anti-Cancer Agent “Perjeta®”
[PDF 300KB] -
Chugai to Give a Course on the “Pharmaceutical Industry”
[PDF 240KB]
at Faculty of Economics, The University of Tokyo -
Organizational and Personnel Changes
[PDF 195KB] -
Chugai to Support Japan Paralympic Committee as an Official Partner
[PDF 206KB] -
Launch of the New Agent for Osteoporosis
[PDF 142KB]
“Bonviva® Injection 1 mg Syringe” -
Roche Diagnostics and Chugai Pharmaceutical Present
[PDF 216KB]
a Biology Science Laboratory Targeting High School Students -
Drug Application Filed for Additional Form of Immunosuppressant,
[PDF 124KB]
“CellCept® Powder for Oral Suspension 32%” -
Organizational and Personnel Changes
[PDF 165KB] -
F. Hoffmann-La Roche Announces Second Quarter Sales 2013
[PDF 16KB] -
Extension of the Shelf-Life for the Anti-Influenza Virus Drug
[PDF 290KB]
Tamiflu®Capsules 75 -
New Agent for Osteoporosis Approved in Japan
[PDF 18KB]
“Bonviva® IV Injection” -
Anti-Cancer Agent “Perjeta®”
[PDF 230KB]
Approved for HER2-positive Inoperable or Recurrent Breast Cancer -
Anti-Cancer Agent “Avastin®,"
[PDF 186KB]
Obtained Approval for Additional Indication and
Dosage and Administration of Malignant Glioma -
Anti-Cancer Agent “Tarceva®,”
[PDF 218KB]
Obtained Approval for Additional Indication (First Line Therapy) of
Non-Small Cell Lung Cancer with EGFR Mutations -
Anti-Cancer Agent, Herceptin®
[PDF 177KB]
Obtained Approval for Dosage and Administration for
Postoperative Adjuvant Chemotherapy in Breast Cancer -
Roche’s RoACTEMRA Shows Long-Term Efficacy
[PDF 251KB]
in Monotherapy and also Benefits in Early Rheumatoid Arthritis -
Roche’s RoACTEMRA Approved in EU
[PDF 263KB]
to Treat Children with Rare Form of Arthritis -
Launch of Subcutaneous Injection Formulation, Actemra®,
[PDF 384KB]
for a Treatment of Rheumatoid Arthritis
The First Anti-IL-6 Receptor Antibody in Subcutaneous Market -
Determination of Terms and Conditions of Stock Options
[PDF 50KB]
(Stock Acquisition Rights) -
Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent,
[PDF 189KB]
AF802, for ALK-Positive Non-Small Cell Lung Cancer
were Published Online on “The Lancet Oncology” -
FDA Approves ACTEMRA® for Children
[PDF 181KB]
Living with a Rare Form of Arthritis -
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 78KB] -
Results of Phase II/III Clinical Trial of Ibandronate Sodium Hydrate
[PDF 22KB]
Injection, Bisphosphonate Antiresorptive Agent,
in Japanese Patients with Osteoporosis Presented -
F. Hoffmann-La Roche Announces First Quarter Sales 2013
[PDF 27KB] -
Dainippon Sumitomo Pharma and Chugai Pharmaceutical
[PDF 32KB]
Terminate Joint Development of Cancer Vaccine -
Personnel Changes
[PDF 124KB] -
Actemra®, a Treatment for Rheumatoid Arthritis
[PDF 55KB]
Obtained Approval for Subcutaneous Injection Formulation -
Chugai to Receive a Letter of Appreciation from
[PDF 301KB]
the Minister of Health, Labour and Welfare for Our Activities to
Support the Victims of the Great East Japan Earthquake -
The Peking University Chugai Medical Foundation Established
[PDF 246KB]
by Chugai’s Donations to Support Peking University’s Medical Students -
FDA Accepts Biologics License Application Submitted for Subcutaneous
[PDF 181KB]
Formulation of ACTEMRA®, a Treatment for Rheumatoid Arthritis -
Filing of Lawsuit on Patent Infringement Concerning Oxarol® Ointment, and
[PDF 67KB]
a Petition for Provisional Disposition Order -
Anti-Cancer Agent, Herceptin®, Filed for Additional Dosage and Administration
[PDF 168KB]
for Postoperative Adjuvant Chemotherapy in Breast Cancer
By “New Drug Application Based on Evidence in the Public Domain” -
Personnel Changes
[PDF 176KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2012
[PDF 45KB] -
New Drug Application Filed for Antibody-Drug Conjugate
[PDF 178KB]
Trastuzumab Emtansine for the Treatment of
HER2-Positive Metastatic or Recurrent Breast Cancer -
Chugai and Debiopharm GroupTMAnnounce an Exclusive License
[PDF 38KB]
Agreement for Anti-Cancer Agent, FF284 (Debio 1347)